LIPO

Lipella Pharmaceuticals Inc. Common Stock

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Lipella Pharmaceuticals Inc. Common Stock (LIPO) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
C
Factor Score 2.5 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 2.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -4.4
Rev Growth YoY -36.4%
Gross Margin N/M
Price Return 3M -34.0%
Price Return 12M -95.4%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.4
ROE -361.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-03 C+ (2.7) C (2.2) C (2.5) C (2.4) C- (2.0) C (2.4)
2026-08-02 C+ (2.7) C (2.2) C (2.5) C (2.4) C- (1.9) C (2.3)
2026-07-29 C+ (2.6) F (0.7) D+ (1.6) F (0.3) D+ (1.5) D (1.3)
2025-06-30 C+ (2.6) F (0.7) D (1.5) F (0.3) D+ (1.5) D (1.3)
2025-03-31 C+ (2.7) D+ (1.5) D+ (1.5) F (0.5) D+ (1.5) D+ (1.5)
Page 1 of 2